Manufacturer
ItalienVitoria, Spain. Main focus in the Dentavis portfolio: regenerative medicine, oral implantology, PRGF-Endoret®, implant systems, digital planning, and clinical continuing education.
550+
Customers in Switzerland
45+
Countries worldwide
Exclusive
Swiss Distribution Partners
About Dentavis
BTI combines implantology with regenerative medicine on a scientific basis — with a strong focus on autologous blood therapies, tissue healing, and clinical research.
BTI is internationally regarded as one of the pioneers in PRP/PRGF therapies. The patented PRGF–ENDORET® technology is the core of the company. It uses the patient's own blood to promote healing and tissue regeneration.
Around 20% of the employees work in research & development. BTI invests heavily in studies, publications, and clinical research — and every profit from product sales flows directly back into research.
PRGF–ENDORET® differs from classic PRP systems through leukocyte-poor preparation. The goal: less inflammation, less postoperative pain, and better tissue healing.
BTI has an excellent reputation worldwide, particularly in implantology and oral surgery. The company combines implant systems with regenerative procedures — implantology plus biological healing optimization.
BTI is active not only in dentistry, but also in orthopedics, sports medicine, dermatology, aesthetics, ophthalmology, sleep medicine, and reproductive medicine.
Today, BTI is active in over 50 countries and has established a strong presence, particularly in Europe and Latin America. Exclusively represented in Switzerland by Dentavis AG.
View documents
Products
Discover the complete range — exclusively distributed by Dentavis in Switzerland.
